愛爾眼科(300015.SZ)半年度淨利潤升36.53%至6.95億元
格隆匯8月22日丨愛爾眼科(300015.SZ)發佈2019年半年度報告，實現營業收入47.49億元，同比增長25.64%；歸屬於上市公司股東的淨利潤6.95億元，同比增長36.53%；歸屬於上市公司股東的扣除非經常性損益後的淨利潤6.95億元，同比增長31.93%；基本每股收益0.2264元。經營活動產生的現金流量淨額9.97億元，同比增長28.14%。
2019年上半年，公司繼續圍繞構建“眼健康生態圈”戰略目標，以“二次創業”精神應對行業發展機遇和挑戰，夯實發展基礎，完善多層次醫療服務，聚集行業高端人才，提升科研學術能力，助力國家青少年近視防控，增強品牌影響力，公司經營業績繼續保持穩健增長。報告期內，公司在上年同期高基數的基礎上實現門診量316.43萬人次，同比增長15.31%；手術量29.96萬例，同比增長7.02%。
報告期內，公司繼續加快醫療網絡佈局，不斷完善省內區域和同城分級連鎖體系，擴大網絡覆蓋範圍，多層次眼科醫療服務逐步落地。一是醫療網絡佈局方面，公司分別收購或新建了湘潭仁和、普洱愛爾、淄博康明愛爾、上海愛爾睛亮等13家醫院及9個門診部或診所；二是醫療服務深化細分方面，公司收購了重慶愛爾兒童眼科醫院，該院專注於各種兒童青少年眼病和先天遺傳性眼病的預防、診療、科普、研究；三是在高端醫療方面，瀋陽愛爾卓越眼科醫院開業，匯聚更多專家名醫，為國內和東北亞高端客户提供國際水準的診療服務，加大力度開拓高端醫療服務市場。
報告期內，公司藉助國際化平台優勢和龐大的醫療網絡體系，加大資源整合力度，推進眼健康生態圈的建設。公司合作投資設立湖南邁歐醫療科技有限公司，穩步延伸拓展產業鏈。同時，公司與華為、拓維信息簽署戰略合作協議，三方將在雲計算、大數據、企業數字化轉型等方面展開合作。另外，公司積極接軌國際產業生態，推動眼科學及視覺科學的臨牀轉化與創新。公司聯合中國研究型醫院學會眼科學與視覺科學專業委員會、新加坡眼科研究所、睿盟希國際視覺科學基金共同主辦第一屆中國國際眼科學和視覺科學轉化與創新論壇，正式啟動“愛爾-睿盟希視覺科學孵化器”，有望提升眼科科技臨牀轉化與自主創新能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
